Home / Transcripts / Myomo, Inc. (MYO) · May 7, 2026

Myomo, Inc. (MYO) Earnings Call Transcript

May 7, 2026

NYSE American US Health Care Health Care Equipment and Supplies earnings 32 min

Earnings Call Speaker Segments

Bruce Voss executive
#1

Thanks, and good afternoon, everyone. Bruce Voss here, calling in from Alliance Advisors IR. I'd like to welcome all of you to the conference call covering Myomo's financial results for the first quarter of 2026. Joining me on the line today are Paul Gudonis, who serves as Myomo's Chief Executive Officer, along with Dave Henry, our Chief Financial Officer. Prior to getting started, I want to remind those listening that anything management says on this call that isn't a historical fact counts as a forward-looking statement. Typically, terms such as anticipate, believe, estimate, expect, intend, guidance, outlook, confidence, target, project, and similar wording serve as signals that identify these forward-looking statements. Such forward-looking statements shouldn't be viewed as guarantees regarding future performance, and they could involve and are subject to risks, uncertainties, and other factors that might impact Myomo's business, financial condition, and operating results. You can find discussion of these risks, uncertainties, and other factors in the filings Myomo has made with the Securities and Exchange Commission. Actual outcomes and results could differ materially from those expressed in or implied by these forward-looking statements. Also, unless the law requires it, Myomo takes on no obligation to revise or update any forward-looking statements so they reflect events or circumstances occurring after today's call date, May 7, 2026. At this point, it's my pleasure to hand the call over to Myomo's CEO, Paul Gudonis. Paul, please go ahead.

Paul Gudonis executive
#2

Thanks, Bruce. Good afternoon, everyone, and thanks for being with us today; we're still really enthusiastic about what's ahead of us — the chance to make lives better and expand our business. Chronic arm and upper limb paralysis is a condition that doesn't get enough attention, and every year strokes leave hundreds of thousands of Americans dealing with lasting arm problems; add spinal cord injury, traumatic brain injury, and brachial plexus injuries into the mix, and the addressable U.S. population climbs into the millions, plus millions more around the world; for the majority of those patients, care has typically meant a passive brace, continual physical therapy that yields less and less, or simply accepting permanent loss of function. In the U.S., the only commercially available powered arm orthosis is MyoPro. It works by using noninvasive EMD sensors that detect the patient's own muscle signals, amplifying them to produce functional movement. As a result, individuals with paralysis can eat on their own, hold items, return to employment, and live more independently at home. This represents not an incremental improvement on existing options, but an entirely new category of device—one that Myomo alone possesses. To illustrate, I'll share a quick real-world case. A member of our team recently worked with Mike, whose right arm became unusable due to a brachial plexus injury from a motorcycle crash when he was only 17. And now, roughly 50 years afterward, he's using both arms once more thanks to a MyoPro. He carries objects safely around his house and handles chores like mowing his lawn. For Mike and his wife, our MyoPro has made life better, easing the care burden caused by his impairment, and that's the whole point of what we do. But a number of favorable factors are coming together at this moment to fuel Myomo's success: reimbursement, distribution, and technology. Reimbursement from CMS under a new Medicare Part B benefit category, with HCPCS codes for MyoPro, has unlocked access to a Medicare population numbering in the tens of millions and knocked down the biggest barrier to adoption there has ever been. New clinical trials, plus in-network contracts signed with a growing number of commercial insurers, have greatly expanded access to the market for patients covered under those plans. Our go-to-market strategy is now moving toward a distribution model rooted in repeat patient referrals coming from rehabilitation hospitals and O&P providers, which should reduce what we spend to acquire customers and set the stage for quicker expansion down the road. The money we put into technology is increasing the value delivered to patients and clinicians alike, while also bringing down our operating expenses as we grow the business to sustain profitability. Back at the start of this year, we established 4 pillars of success for 2026: recurring revenue, market access, operating leverage, and innovation. We made strong headway on every one of those items, and as a result, our Q1 top line and bottom line came in above plan. Because those four pillars are how we measure success, I'd like to go through them one at a time. Starting with expanding recurring patient sources: in the middle of 2025 we launched MyoConnect, which lets therapists and physicians at rehabilitation hospitals, stroke clinics, and other care facilities send potential MyoPro users either directly to us or to a nearby O&P partner. Through those channels we get not only repeat referrals but also cheaper patient acquisition and higher conversion than we see from marketing directly to patients. Once Medicare reimbursement was in place and we had launched the MyoPro 2x last year, we felt the moment had come to bring the benefits of MyoPro to the incidence group — patients currently receiving outpatient therapy — which moves our addressable market beyond those living with long-term arm paralysis and the sizable prevalence group. We restructured our field clinical team, hired sales specialists, and conducted many in-service education sessions at those rehabilitation sites. I'm pleased to report that over 150 rehab centers are now referring candidates to us. The O&P channel provides an additional stream of repeat referrals, and our O&P revenue rose 79% compared with a year earlier as we trained and certified more CPOs and worked together on outreach initiatives. At the start of this week, we shared news that a collaboration has been underway with Ottobock's U.S. clinical operations aimed at getting them certified as MyoPro Centers of Excellence. Not long ago, we also ran a training session that brought together more than 20 clinical specialists from across the country, which is part of their national rollout effort. When it comes to O&P products and clinical services, Ottobock stands as the largest provider globally, and it's a real pleasure for us to collaborate so closely with them. Over in Germany, upwards of 100 O&P practices are already teaming up with us to bring the MyoPro to their patients. Germany's insurance landscape is extremely favorable, and our international revenues hit a Q1 record of roughly $2 million. Our sales and clinical teams in Germany keep growing, and we'll be at the OTWorld Conference in Leipzig later this month to connect with more O&P clinics. In Europe, that gathering is the biggest O&P event there is. Thanks to all this work, we're doing very well when measured against our goals for steadily growing revenue from recurring patient sources. Pillar #2 — the second of our success pillars — involves boosting patient access to the market by getting more payer contracts signed. Back in March, as we talked about, we completed a national deal with Elevance, which oversees several Anthem Blue Cross Blue Shield plans across 27 states, among them big ones such as Texas, Ohio, Virginia and California. We have been signing these agreements with payers so that Myomo is set up as an in-network provider, with coverage decisions made on a case-by-case basis and a set price for the MyoPro. Because of that, the authorization rate we're getting from these payers' Medicare Advantage and commercial plans is now much higher. And in the months ahead, I anticipate we will sign more state contracts through the Elevance national arrangements. After we obtained Medicare coverage in April of 2024 and brought on a range of commercial and Medicare Advantage contracts, our covered lives have grown from only 9 million to 158 million at present. Pillar #3 is about showing operating leverage and the route to profitability. During the first quarter, we showed early operating leverage, as revenue rose 3% while OpEx declined 1% compared with the same period a year earlier. Gross margin also improved by 100 basis points, and together these gains produced a 20% increase in adjusted EBITDA. Our fourth pillar involves continuing to put money into product development and clinical research. At the close of March, we released a new mobile app that lets clinicians, patients, and caregivers adjust MyoPro device settings from their smartphones, view muscle movements and EMG signals, and gather usage data that therapists and physicians can draw on. This app additionally removes the need to send a laptop loaded with our proprietary software to every user, which lowers our MyoPro material cost by roughly 10%. That benefit will begin showing up in gross margin starting in the second quarter. A randomized control trial run by the University of Utah Rehabilitation Hospital represents another R&D investment. Following a successful pilot a year ago, the university's IRB gave approval to a study comparing outcomes for MyoPro users with those for people who got the present standard of care, occupational therapy. So far we have enrolled 18 of the 50 subjects, and once the study is finished, assuming results resemble those from last year's pilot, this clinical evidence should help secure higher reimbursement for MyoPro. Last, work on the MyoPro 3 next-generation platform continues to move forward. Our emphasis is on better functionality and greater processing power to enable future software driven innovations. Each of our 4 success pillars is advancing in line with our targets, and we're eager to keep delivering. On the marketing side, we brought in a new marketing executive and brought on a new digital ad agency during Q1. Consequently, we have sharpened our marketing strategy through a fresh approach to digital channels and data-driven targeting. We're also expanding how we use social platforms to reach healthcare providers directly and to introduce MyoPro into regions where payer contracts are in place. Those initiatives are already improving the quality of our leads, which means each lead we generate produces more additions to the pipeline and reduces what we spend to acquire patients; we expect further efficiency improvements as these programs grow throughout 2026. That covers my remarks, and I'll now turn things over to Dave Henry, our CFO, who will walk through the financial results in more depth.

Dave Henry executive
#3

Thanks, Paul, and good afternoon to all of you. Like Paul just mentioned, we've stayed busy carrying out the success pillars that we rolled out earlier this year, and I'm happy to walk you through how far we've come. Revenue in the first quarter of 2026 came in at $10.1 million, which is a 3% gain over the same period last year. That rise came from a higher average selling price, or ASP, though it was partly offset by a modest decline in revenue units. ASP during the first quarter reached $58,800, a 9% increase over the prior year, thanks to larger Medicare Part B and Medicare Advantage reimbursement amounts tied to beginning of year fee updates, plus favorable channel mix, such as greater international and Medicare Advantage revenues. We shipped 172 MyoPro revenue units in the quarter. Turning to payer mix, Medicare Part B patients in our direct billing channel accounted for 51% of first quarter revenue, a 12% drop in dollar terms from the prior year. Medicare Advantage patients within our direct billing channel made up 19% of first quarter revenue, and in dollar terms that was 11% higher than the prior year quarter. As plenty of healthcare providers are experiencing, the macro environment for Medicare Advantage plans remains difficult. To soften the impact, we're concentrating on in-network patients secured through our contracting work, where early results show better authorization rates than what we see with non-contracted payers. The direct billing channel made up 71% of first quarter revenue, versus 79% in the prior year quarter. Direct billing revenue fell as we kept moving our business toward recurring patient sources. Revenue from recurring patient sources accounted for 49% of first quarter revenue, an increase from 25% in the prior year. As you can tell, we've achieved meaningful progress in shifting toward recurring patient sources at a lower patient acquisition cost than advertising-driven direct patient revenues, which come with a far higher cost to acquire. Breaking out the recurring patient sources, roughly 20% of first quarter revenue came from direct billing referrals. Another 20% came from the international channel, 8% came from the U.S. O&P channel, and VA payers made up the remainder. International revenue climbed 53% year-over-year, while the U.S. O&P channel rose 79% year-over-year. As of March 31, 2026, the pipeline totaled 1,680 patients, which is a 10% sequential increase and a 13% year-over-year increase. In the first quarter, we added 723 patients to the pipeline, up 7% sequentially and 3% year-over-year. 11% of first quarter pipeline adds came from direct billing referrals, showing the traction achieved so far with the MyoConnect program. 62% of first quarter revenue units were intra-fill revenue units, up from 45% of revenue units a year ago, which shows our greater velocity in fulfilling orders. 16% of first quarter orders originated from direct billing referrals. We closed the quarter with a backlog of 226 patients. In the first quarter of 2026, gross margin came in at 68.2%, compared with 67.2% during the same period last year. The gain came from a higher ASP and reductions in material costs, though these were partly offset by increased labor and travel costs required to fit patients on site. Operating expenses totaled $10.1 million in the first quarter of 2026, a decline of 1% versus the prior year quarter. The decrease mainly reflected lower R&D and G&A expenses, partly offset by greater sales, clinical and marketing expenses. Our operating loss for the first quarter of 2026 was $3.2 million, narrower than the $3.5 million operating loss recorded in the prior year quarter. Adjusted EBITDA in the first quarter of 2026 was negative $2.3 million, versus negative $2.8 million in the prior year quarter. This improvement stemmed from the smaller operating loss I just referenced along with larger add backs for depreciation expense and stock-based compensation. Nonoperating income in the first quarter includes a mark-to-market gain tied to the change in fair value of derivative liabilities, partly offset by cash and noncash interest expense under the Avenue Capital term loan. For the first quarter of 2026, net loss was $3 million, or $0.07 per share; that compares with a net loss of $3.5 million, or $0.08 per share, in the prior year quarter. Now let's look at our balance sheet and cash flow. At March 31st, 2026, cash equivalents and short-term investments stood at $15.7 million. Mirroring the improvement in adjusted EBITDA, cash used during the first quarter was $2.7 million, versus $3.2 million used in the first quarter of 2025. I'll wrap up my remarks with our forward-looking guidance. As you've just heard, we're making tremendous progress on our 2026 objectives; during the first quarter, we delivered higher year-over-year revenue, better gross margin and reduced operating expenses, which produced improved adjusted EBITDA. Our shift of the business toward recurring patient sources is ahead of plan. On top of that, the marketing changes we initiated are starting to take effect. Consequently, we anticipate second quarter revenue in the range of $10.3 million to 10.8 million, which represents 7% to 12% growth year-over-year and 2% to 7% growth sequentially. We expect gross margin in the second quarter to be higher year-over-year, yet lower sequentially, due primarily to channel mix; we expect operating expenses to rise slightly versus the first quarter, reflecting a modest increase in advertising spending; for the full year, we are reiterating our revenue guidance in the range of $43 million to $46 million, and we affirm our full year operating leverage expectation to limit the growth of operating expenses in 2026 to about one half the growth of revenue. With that financial overview, I'll turn the call back to Paul.

Paul Gudonis executive
#4

Appreciate that, Dave. So, in short, we remain sharply concentrated on putting our four success pillars into action so that MyoPro volume and revenues increase, all while key financial metrics get better — gross margin, adjusted EBITDA, and cash usage among them. For patients dealing with this chronic arm paralysis, our technology is delivering a dramatic change in their lives; so Dave and I are now prepared to field your questions. Operator? As we wait for that first question, I want to note that during May, we'll be taking part in the Sidoti Virtual Investor Conference along with A.G.P.'s annual healthcare company showcase; then on June 23r and 24, we'll present at the iAccess Alpha Select Virtual Conference and hold one-on-one meetings with investors. All right, operator, whenever you're ready, let's go ahead with the first question.

Chase Knickerbocker analyst
#5

Perhaps to start with the ASP gain, could you elaborate a bit further on what was behind it — specifically the mix you mentioned and which drivers inside that mix pushed ASP up or down? Then my follow-up, I suppose, is simply how long can that last? What's the right way to think about ASP on a sequential basis across the year?

Dave Henry executive
#6

Yes, sure. ASP stood at $58,800. Part of that rise came from the fee increase, which, as you know, takes effect each year at the start with CMS. Medicare Advantage payers felt that too. So Medicare together with Medicare Advantage accounted for roughly 70% of revenues during the first quarter, and every one of those was subject to the fee increase. On top of that, international revenues give us a bit of a foreign currency tailwind. International ranks as our second-biggest channel by revenues and by ASP alike, and it made up 20% of revenue. That explains it. As for how long it lasts, my expectation is that channel mix will pull ASP down somewhat in the second quarter. And I'd say it remains sensible to assume an ASP of roughly $55,000 or thereabouts over a longer-term horizon.

Chase Knickerbocker analyst
#7

Got it. Perhaps regarding the advertising efficiency area, could you sort of unpack how much of a percentage benefit came during the quarter from MyoConnect? Did MyoConnect account for most of that drop in cost per pipeline ad, or were there certain gains you're observing when it comes to digital marketing?

Dave Henry executive
#8

As far as the metrics go, MyoConnect represented 11% of the pipeline ads in the quarter, and those arrive at a low cost per pipeline ad, though we aren't advertising to obtain those. That's a significant portion of it. And then there are the efficiencies we're witnessing, as Paul mentioned, we're experiencing a lower cost, or more pipeline ads per lead, that we generate via some of these efforts we're undertaking.

Paul Gudonis executive
#9

The lead quality problem we had 12 months back, Chase, has genuinely reversed course. At this point, a greater share of the leads we receive are producing results; we're connecting with those patients, and since they meet medical criteria, they're entering the pipeline. We also overhauled our TV advertising, introducing a fresh 120-second spot. That investment has delivered strong returns. A solid cost per call, and the patients who watch it, or their caregivers, are highly engaged; so those 2 factors together have brought down our cost per pipeline ad.

Chase Knickerbocker analyst
#10

So you brought up the idea that we'd be stepping up certain marketing outlays as the year progresses and we move into Q2. Is that mostly because you're seeing things get better in that area? Or perhaps you could walk me through what's really fueling that sort of reinvestment.

Dave Henry executive
#11

Yeah. I'd agree that's true, and it's likewise a thing we generally do annually. Our biggest advertising outlays tend to land in the second and third quarters, after which they drop back down once again in the fourth quarter, simply due to the efficiencies that occur in the fourth quarter — or the inefficiencies, I ought to say, that occur in the fourth quarter.

Paul Gudonis executive
#12

Also, because of how long it takes to collect revenue — anywhere from four to six months, sometimes more, based on what the patient's insurance is — the advertising we're doing right now is creating a solid pipeline and backlog that will feed Q3 and Q4 revenue.

Chase Knickerbocker analyst
#13

Then, to wrap up from my side. The guidance implies an acceleration in growth during the back half. The guidance was reaffirmed, and the quarterly mix came in somewhat differently from what we had more or less anticipated. Could you take us through what the upper bound of your guidance presumes as well as the lower bound, in terms of the various moving parts and the assumptions baked in?

Dave Henry executive
#14

At the high end of the guidance, I'd say that would mostly be a function of the direct billing channel, especially when it comes to greater traction on the referrals front. MyoConnect, I'd say, is likely the largest swing factor where our guidance is concerned. For instance, positive developments and solid momentum with that, which is what we've observed up to now, would push us to gravitate toward the upper bound of our guidance. Should some — if for whatever reason that were to — should a portion of those outcomes start to level off or decline, that would steer us — that would push us in the direction of the lower bound of our guided range.

Ed Woo analyst
#15

Yes. Nice work on the quarter. I wanted to ask about our business abroad. You turned in yet another really impressive period, with excellent expansion and all-time-high revenue. What kind of room does the German market offer, and could we speed up that expansion in the short term?

Paul Gudonis executive
#16

Well, if you consider Germany, it has more than 80 million people, versus roughly 330 million in the U.S., so that works out to somewhere between 25% and 30% of what the U.S. market amounts to overall. So clearly, meaningful upside exists in that country. And as we have observed, thanks to statutory health insurance and social court decisions in that country, we are gaining solid momentum with the insurers located there, and that is why we keep investing more people and money, since that is how you expand the German operation. Later this month I will be in Leipzig, Germany, attending the OTWorld Conference, in order to bring in additional O&P providers. We are also going to begin exploring a few other markets outside the U.S.

Ed Woo analyst
#17

That sounds good. You brought up other markets outside the US. I recall you saying before that Germany was a somewhat special case. What about other European countries, or maybe markets in different regions? Is there anything new regarding China?

Paul Gudonis executive
#18

Well, likely the other European countries where reimbursement can be obtained fairly fast. So we'll speak with a number of O&P providers in those nations to learn how they view the reimbursement landscape, so that — we always consider where to put another euro, where the best spot is to invest; up to now, Germany has delivered the strongest return. Staying within Europe would also let us take advantage of the infrastructure we already have there; when it comes to China, we keep talking with Chinaleaf ventures, one of the biggest investors in the joint venture. We've been having regular discussions to bring in new potential partners, medical device manufacturers and investment partners to the JV, but as far as the next step with the JV goes, nothing over there has been finalized.

Jeremy Pearlman analyst
#19

Yes. First off, I'd like to discuss MyoConnect. You said there were approximately 150 rehab facilities referring patients at present. How big do you figure that opportunity is? What's the count of additional rehab clinics in the pipeline that could be converted to MyoConnect?

Paul Gudonis executive
#20

Well, Jeremy, we've seen incredible results in only the first 9 months, ever since we launched that in mid-2025. My expectation is that we'll bring on additional clinics each month. It would be great to reach a point of having several hundred by the time this year ends. So there are roughly 1,500 stroke clinics across the U.S., along with plenty of other large hospitals that provide care for stroke patients. And beyond that, we're achieving a great deal of success with the smaller private rehab clinics. There are therapists who run their own clinic, and they send MyoPro patients our way. So our aim is to expand the number of rehab facilities to a couple hundred by year's end. Also observe what I refer to as same-store sales growth, where following that initial patient referral, they'll send a couple of others, and that ought to increase not just this year, but far into next year. That's the reason I believe we're building the groundwork for faster growth next year. You can picture hundreds of these clinics, then expanding the number of patients they refer next year, along with new clinics that join next year as MyoConnect partners. And in addition, you have an increasing number of O&P providers joining; so we recently announced Ottobock. They have more than 50 locations throughout the U.S. We just provided training to 20 some of their clinicians across the country. They're going to be getting the word out within their territories. We have another major national account prepared for a similar kind of training underway.

Jeremy Pearlman analyst
#21

All right, that sounds excellent. And as a quick follow-up, you said you're hoping this serves as the groundwork for faster expansion. What they're doing — ideally, they will send patients to these clinics. After the initial patient is referred by them, additional ones will follow. Can we say yet whether that's happening? Has that pattern shown up among the rehab clinics already running the MyoConnect program? Does it leave you feeling confident that a significant jump could arrive in 2027?

Paul Gudonis executive
#22

Those kinds of early signs are beginning to appear. Keep in mind that nearly all of them have only recently launched. Their initial referral came in December or January, after which the patient must navigate the insurance process, get fitted with the device, and then visit that clinic for therapy services, and only then is the outcome visible; so from the first referral to our second one, 6 months may pass; even so, given how our device performs for these patients, I have confidence that these referrals will keep coming.

Jeremy Pearlman analyst
#23

All right, got it. And one more thing, building off that earlier question about MyoConnect. When patients come in via that program, does a larger share of them ultimately move from the backlog and become paying customers, or does it look the same as your traditional direct-to-consumer advertising, which brings in patients and then some percentage falls away, with whatever remains going on to the final MyoPro?

Paul Gudonis executive
#24

Yeah. Good point. Really good point, actually, since these patients are superior on 2 fronts. First, the clinicians doing the referrals have been taught by us to screen these patients ahead of time for us. The quality of patients they send is better, which means, medically speaking, they're more likely to gain from MyoPro. So that's a positive. Compared with people who arrive through general advertising, they're a higher-quality patient. Second, since these clinicians are aware that Medicare will pay for this, the share of Medicare they send us is larger than what you'd see in the broader population; so from these MyoConnect program referrals, it amounts to a double win, essentially.

Jeremy Pearlman analyst
#25

All right, that sounds excellent. I follow you. So, one final item. At your Investor Day last year, I recall you spoke about a significant piece — there was a portion focused on fighting denials of claims. I'm just curious if there's any update, perhaps how that's going — what's the success rate looking like? Is it holding steady? Has there been an improvement? If you could share anything on that, it would be appreciated.

Paul Gudonis executive
#26

Sure. These ALJ hearings are something we keep pursuing. The success rate remains roughly at that same level. That said, as we noted, in situations where we hold contracts with those different plans, our authorization rate is far greater from the very start, meaning we avoid needing to reach the hearings at all.

Paul Gudonis executive
#27

Alright, thanks, operator. I appreciate everyone being here today and for the questions you've raised. We're eager to connect with and hear from all of you over the next few months. Thanks once more. Enjoy your evening.

Operator operator
#28

That brings us to the end of today's conference call. At this point, you're free to disconnect your lines. Thanks for joining us, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Myomo, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Myomo, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.